Philip W. Lam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philip W. Lam has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Jerome A. Leis
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
10 shared publicationsNick Daneman
Department of Medicine, University of Toronto, Toronto, Canada
8 shared publications- Jerome Allen Leis
Sunnybrook Health Sciences Centre
6 shared publications Marion Elligsen
Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada
6 shared publications- Nick Daneman
Public Health Ontario
6 shared publications Nisha Andany
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Canada
4 shared publications
Latest Publications
- 17 December 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (4) , 319-324
Salmonella Typhi mimicking Pott's disease: A case report and review of the literature
Background: Infectious spondylodiscitis, an infection that involves the intervertebral disc and adjacent vertebral body, often manifests as back pain, fever, and malaise. Although Staphylococcus aureus is the most commonly reported cause of infectious spondylodiscitis, other atypical organisms can also cause spinal infections. Salmonella enterica serovar Typhi has been rarely reported to cause spondylodiscitis. Method: Retrospective single-record review with informed written consent from the patient. Results: We present the case of an immunocompetent 67-year-old female patient with subacute intermittent back pain, weight loss, and a history of prolonged travel to India. MRI showed destructive T7–T8 spondylodiscitis with vertebral collapse, kyphotic deformity, and severe canal stenosis. Given the patient's presentation, epidemiology, and radiologic features, spinal tuberculosis was initially suspected. A biopsy of the spinal tissue grew S. Typhi by the third day of incubation. The patient was treated with a 6-week course of intravenous ceftriaxone. The patient's symptoms resolved over the course of treatment, and she remained clinically well with no signs of recurrent infection at 12-month follow-up. Conclusion: This case highlights S. Typhi as a rare cause of spondylodiscitis in immunocompetent individuals that can mimic Pott's disease clinically and radiographically. This case exemplifies the importance of maintaining a broad differential when evaluating spondylodiscitis, especially in patients who travel to regions that are endemic for atypical pathogens.
- 17 December 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (4) , 319-324
Salmonella Typhi mimicking Pott's disease: A case report and review of the literature
Background: Infectious spondylodiscitis, an infection that involves the intervertebral disc and adjacent vertebral body, often manifests as back pain, fever, and malaise. Although Staphylococcus aureus is the most commonly reported cause of infectious spondylodiscitis, other atypical organisms can also cause spinal infections. Salmonella enterica serovar Typhi has been rarely reported to cause spondylodiscitis. Method: Retrospective single-record review with informed written consent from the patient. Results: We present the case of an immunocompetent 67-year-old female patient with subacute intermittent back pain, weight loss, and a history of prolonged travel to India. MRI showed destructive T7–T8 spondylodiscitis with vertebral collapse, kyphotic deformity, and severe canal stenosis. Given the patient's presentation, epidemiology, and radiologic features, spinal tuberculosis was initially suspected. A biopsy of the spinal tissue grew S. Typhi by the third day of incubation. The patient was treated with a 6-week course of intravenous ceftriaxone. The patient's symptoms resolved over the course of treatment, and she remained clinically well with no signs of recurrent infection at 12-month follow-up. Conclusion: This case highlights S. Typhi as a rare cause of spondylodiscitis in immunocompetent individuals that can mimic Pott's disease clinically and radiographically. This case exemplifies the importance of maintaining a broad differential when evaluating spondylodiscitis, especially in patients who travel to regions that are endemic for atypical pathogens.
- Open Access
- 4 November 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (2) , 223-224
Antibiotic-exposure guided prevalence screening for vancomycin-resistant Enterococcus: better value for hospitals
- 4 November 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (2) , 223-224
Open AccessAntibiotic-exposure guided prevalence screening for vancomycin-resistant Enterococcus: better value for hospitals
- Open Access
- 8 October 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e69140
Monitoring People With COVID-19 at Home With the COVIDFree@Home Program: Feasibility Cohort Study
Background: During the COVID-19 pandemic, many with acute infection isolated at home, with a small but significant number requiring hospitalization. At the time, since the pathogen was fairly unknown, clinicians were uncertain about which patients would rapidly deteriorate and need hospitalization. We developed the COVIDFree@Home smartphone app and clinician dashboard to monitor and support people managing at home with acute COVID-19 infection. It was uncertain whether such an app would be used by patients and whether it would support patient care. This knowledge would inform telemedicine and digital health tools being used to deliver care to patients remotely at that time. Objective: This study aimed to determine the feasibility of using a smartphone app and clinician dashboard for remote clinical monitoring of people with COVID-19 at home. Methods: A feasibility study set at 3 hospital sites (University Health Network, Sunnybrook Health Sciences Centre, and Trillium Health Partners) between 2020 and 2022 was conducted. Participants newly diagnosed with COVID-19 were asked to enter data into a smartphone app called COVIDFree@Home twice daily for 10 days while isolating at home. Their data, including symptoms, temperature, and oxygen saturation, were monitored on a clinician-facing dashboard. The primary outcome of feasibility was the number of patients who used the app. We also examined patient satisfaction through a survey questionnaire. Results: A total of 431 patients were recruited, out of which 229 (56.5%) were females and the average age was 38.9 (SD 12.8) years. There were 376 (87.2%) participants who used the app to report symptoms or oxygen saturation at least once. Among these participants, 373 (99.2%) reported symptoms and 363 (96.5%) reported oxygen saturation. Participants reported symptoms an average of 1.7 (SD 1.1) times per day for a median of 5 (IQR 3‐8) days. Oxygen saturation levels were reported 1.5 times per day for a median of 6 (IQR 4‐9) days. There were 19 hospitalizations (4.4%) among study participants. Most patients felt comfortable using the app, felt reassured their data was being monitored and did not have privacy concerns. Conclusions: Patients with acute COVID-19 infection engaged with a remote home monitoring platform, however, not at the recommended frequency or duration. Remote patient monitoring of acute respiratory infection appears viable and can offer patients reassurance. It has the potential to reduce strain on the health care system during future pandemics, but further evidence is required to demonstrate improved health outcomes.
- 8 October 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e69140
Open AccessMonitoring People With COVID-19 at Home With the COVIDFree@Home Program: Feasibility Cohort Study
Background: During the COVID-19 pandemic, many with acute infection isolated at home, with a small but significant number requiring hospitalization. At the time, since the pathogen was fairly unknown, clinicians were uncertain about which patients would rapidly deteriorate and need hospitalization. We developed the COVIDFree@Home smartphone app and clinician dashboard to monitor and support people managing at home with acute COVID-19 infection. It was uncertain whether such an app would be used by patients and whether it would support patient care. This knowledge would inform telemedicine and digital health tools being used to deliver care to patients remotely at that time. Objective: This study aimed to determine the feasibility of using a smartphone app and clinician dashboard for remote clinical monitoring of people with COVID-19 at home. Methods: A feasibility study set at 3 hospital sites (University Health Network, Sunnybrook Health Sciences Centre, and Trillium Health Partners) between 2020 and 2022 was conducted. Participants newly diagnosed with COVID-19 were asked to enter data into a smartphone app called COVIDFree@Home twice daily for 10 days while isolating at home. Their data, including symptoms, temperature, and oxygen saturation, were monitored on a clinician-facing dashboard. The primary outcome of feasibility was the number of patients who used the app. We also examined patient satisfaction through a survey questionnaire. Results: A total of 431 patients were recruited, out of which 229 (56.5%) were females and the average age was 38.9 (SD 12.8) years. There were 376 (87.2%) participants who used the app to report symptoms or oxygen saturation at least once. Among these participants, 373 (99.2%) reported symptoms and 363 (96.5%) reported oxygen saturation. Participants reported symptoms an average of 1.7 (SD 1.1) times per day for a median of 5 (IQR 3‐8) days. Oxygen saturation levels were reported 1.5 times per day for a median of 6 (IQR 4‐9) days. There were 19 hospitalizations (4.4%) among study participants. Most patients felt comfortable using the app, felt reassured their data was being monitored and did not have privacy concerns. Conclusions: Patients with acute COVID-19 infection engaged with a remote home monitoring platform, however, not at the recommended frequency or duration. Remote patient monitoring of acute respiratory infection appears viable and can offer patients reassurance. It has the potential to reduce strain on the health care system during future pandemics, but further evidence is required to demonstrate improved health outcomes.
- 27 June 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (2) , 179-185
Trends in oral antibiotic treatment in patients hospitalized with diabetic foot osteomyelitis: A single-centre experience
Background: The Oral Versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA) trial demonstrated the efficacy of highly bioavailable oral antibiotic therapy for the treatment of osteoarticular infections. However, there continues to be significant variability in practice. This study aimed to assess changes in oral antibiotic use in the treatment of diabetic foot osteomyelitis (DFO) at a large academic hospital. Methods: We conducted a retrospective cohort study of adult patients admitted to Sunnybrook Health Sciences Centre from January 1, 2016, to December 31, 2022, with a diagnosis of DFO. The primary outcome was the proportion of patients who received definitive oral antibiotic treatment during two timeframes (Pre-OVIVA publication: January 1, 2016, through February 28, 2019, and post-OVIVA publication: March 1, 2019, to December 31, 2022). Patients were excluded if they had another indication for long-term intravenous antibiotics, if they did not receive antibiotic treatment for osteomyelitis, or if they underwent amputation without the need for postoperative antibiotics. Results: A total of 145 patients were included in the analysis. (65 patients pre-OVIVA and 80 patients post-OVIVA). The majority of patients had a history of peripheral arterial disease (59%) and gangrene (66%) present on hospital admission. Use of definitive oral antibiotic therapy increased from 10.8% in the pre-OVIVA period to 21.2% in the post-OVIVA period ( p = 0.14). Conclusions: There was a trend toward increased definitive oral antibiotic therapy for DFO, but overall use remained low. Further studies are needed to explore the factors influencing the selection of oral antibiotic therapy in this population.
- 27 June 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (2) , 179-185
Trends in oral antibiotic treatment in patients hospitalized with diabetic foot osteomyelitis: A single-centre experience
Background: The Oral Versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA) trial demonstrated the efficacy of highly bioavailable oral antibiotic therapy for the treatment of osteoarticular infections. However, there continues to be significant variability in practice. This study aimed to assess changes in oral antibiotic use in the treatment of diabetic foot osteomyelitis (DFO) at a large academic hospital. Methods: We conducted a retrospective cohort study of adult patients admitted to Sunnybrook Health Sciences Centre from January 1, 2016, to December 31, 2022, with a diagnosis of DFO. The primary outcome was the proportion of patients who received definitive oral antibiotic treatment during two timeframes (Pre-OVIVA publication: January 1, 2016, through February 28, 2019, and post-OVIVA publication: March 1, 2019, to December 31, 2022). Patients were excluded if they had another indication for long-term intravenous antibiotics, if they did not receive antibiotic treatment for osteomyelitis, or if they underwent amputation without the need for postoperative antibiotics. Results: A total of 145 patients were included in the analysis. (65 patients pre-OVIVA and 80 patients post-OVIVA). The majority of patients had a history of peripheral arterial disease (59%) and gangrene (66%) present on hospital admission. Use of definitive oral antibiotic therapy increased from 10.8% in the pre-OVIVA period to 21.2% in the post-OVIVA period ( p = 0.14). Conclusions: There was a trend toward increased definitive oral antibiotic therapy for DFO, but overall use remained low. Further studies are needed to explore the factors influencing the selection of oral antibiotic therapy in this population.
- 27 June 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (2) , 105-111
Use of oral antibiotic therapy for prosthetic joint infections: Considerations for implementation of interdisciplinary practice changes
- 27 June 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (2) , 105-111
Use of oral antibiotic therapy for prosthetic joint infections: Considerations for implementation of interdisciplinary practice changes
- Open Access
- 28 February 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e70
Impact of two antimicrobial susceptibility reporting strategies on treatment of bacteremia caused by low-risk AmpC inducible organisms
In this retrospective study examining the treatment of low-risk AmpC-producing Enterobacterales bacteremia during two periods with different microbiology reporting strategies, reporting of ceftriaxone susceptibility was associated with a statistically significant decrease in carbapenem use as definitive therapy compared to when susceptibility was suppressed (21 vs 50%, p < 0.0001).
- 28 February 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e70
Open AccessImpact of two antimicrobial susceptibility reporting strategies on treatment of bacteremia caused by low-risk AmpC inducible organisms
In this retrospective study examining the treatment of low-risk AmpC-producing Enterobacterales bacteremia during two periods with different microbiology reporting strategies, reporting of ceftriaxone susceptibility was associated with a statistically significant decrease in carbapenem use as definitive therapy compared to when susceptibility was suppressed (21 vs 50%, p < 0.0001).
- Open Access
- 10 October 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (11) , 1366-1369
Factors influencing the use of highly bioavailable oral antibiotic therapy for the treatment of prosthetic joint infections
We conducted a retrospective cohort study to identify factors influencing intravenous (IV) versus oral antibiotic therapy in first-episode prosthetic joint infections. Of the 34/78 (44%) cases treated intravenously, negative cultures (26%), concomitant infections necessitating IV antibiotics (21%), and delays in susceptibility testing (15%) were the most common reasons for IV therapy.
- 10 October 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (11) , 1366-1369
Open AccessFactors influencing the use of highly bioavailable oral antibiotic therapy for the treatment of prosthetic joint infections
We conducted a retrospective cohort study to identify factors influencing intravenous (IV) versus oral antibiotic therapy in first-episode prosthetic joint infections. Of the 34/78 (44%) cases treated intravenously, negative cultures (26%), concomitant infections necessitating IV antibiotics (21%), and delays in susceptibility testing (15%) were the most common reasons for IV therapy.
- 1 July 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (11) , 1716-1723
Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting
Alemtuzumab is a potent lymphocyte-depleting immunotherapy used in solid organ transplan-tation (SOT), that is increasingly being applied in diverse lymphoproliferative disorders (LPDs). However, a significant toxicity limiting expanded usage is cytomegalovirus (CMV) infection, for which standardized preventive strategies exist in SOT but not in LPDs due to a poor understanding of infection risk in this population, with early LPD studies largely limited to stem cell transplantation. Using one of the most diverse arrays of LPDs studied to date, our retrospective cohort study of non-transplant patients receiving alemtuzumab over a ten-year period at a large regional cancer center examines the incidence and clinical profile of infected patients. Among 24 patients, we identified a composite CMV infection rate of 42% with a symptomatic rate of 21%. We also noted significant variations in preventive strategies, which alongside a high infection rate presents an opportunity to improve outcomes through further work in standardization.
- 1 July 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (11) , 1716-1723
Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting
Alemtuzumab is a potent lymphocyte-depleting immunotherapy used in solid organ transplan-tation (SOT), that is increasingly being applied in diverse lymphoproliferative disorders (LPDs). However, a significant toxicity limiting expanded usage is cytomegalovirus (CMV) infection, for which standardized preventive strategies exist in SOT but not in LPDs due to a poor understanding of infection risk in this population, with early LPD studies largely limited to stem cell transplantation. Using one of the most diverse arrays of LPDs studied to date, our retrospective cohort study of non-transplant patients receiving alemtuzumab over a ten-year period at a large regional cancer center examines the incidence and clinical profile of infected patients. Among 24 patients, we identified a composite CMV infection rate of 42% with a symptomatic rate of 21%. We also noted significant variations in preventive strategies, which alongside a high infection rate presents an opportunity to improve outcomes through further work in standardization.
- Open Access
- 18 December 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e245
Patient predictors of pathogenic versus commensal Gram-positive bacilli organisms isolated from blood cultures
Objective: Gram-positive bacilli represent a diverse species of bacteria that range from commensal flora to pathogens implicated in severe and life-threatening infection. Following the isolation of Gram-positive bacilli from blood cultures, the time to species identification may take upward of 24 hours, leaving clinicians to conjecture whether they may represent a contaminant (inadvertent inoculation of commensal flora) or pathogenic organism. In this study, we sought to identify patient variables that could help predict the isolation of contaminant versus pathogenic Gram-positive bacilli from blood cultures. Design: Retrospective cohort study. Settings: One quaternary academic medical center affiliated with the University of Toronto. Patients: Adult inpatients were admitted to hospital over a 5-year period (May 2014 to December 2019). Methods: A total of 260 unique Gram-positive bacilli blood culture results from adult inpatients were reviewed and analyzed in both a univariable and multivariable model. Results: Malignancy (aOR 2.78, 95% CI 1.33–5.91, p = 0.007), point increments in the Quick Sepsis Related Organ Failure Assessment score for sepsis (aOR 2.25, 95% CI 1.50–3.47, p < 0.001), peptic ulcer disease (aOR 5.63, 95% CI 1.43–21.0, p = 0.01), and the receipt of immunosuppression prior to a blood culture draw (aOR 3.80, 95% CI 1.86–8.01, p < 0.001) were associated with an increased likelihood of speciating pathogenic Gram-positive bacilli from blood cultures such as Clostridium species and Listeria monocytogenes. Conclusion: Such predictors can help supplement a clinician’s assessment on determining when empirical therapy is indicated when faced with Gram-positive bacilli from blood cultures and may direct future stewardship interventions for responsible antimicrobial prescribing.
- 18 December 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e245
Open AccessPatient predictors of pathogenic versus commensal Gram-positive bacilli organisms isolated from blood cultures
Objective: Gram-positive bacilli represent a diverse species of bacteria that range from commensal flora to pathogens implicated in severe and life-threatening infection. Following the isolation of Gram-positive bacilli from blood cultures, the time to species identification may take upward of 24 hours, leaving clinicians to conjecture whether they may represent a contaminant (inadvertent inoculation of commensal flora) or pathogenic organism. In this study, we sought to identify patient variables that could help predict the isolation of contaminant versus pathogenic Gram-positive bacilli from blood cultures. Design: Retrospective cohort study. Settings: One quaternary academic medical center affiliated with the University of Toronto. Patients: Adult inpatients were admitted to hospital over a 5-year period (May 2014 to December 2019). Methods: A total of 260 unique Gram-positive bacilli blood culture results from adult inpatients were reviewed and analyzed in both a univariable and multivariable model. Results: Malignancy (aOR 2.78, 95% CI 1.33–5.91, p = 0.007), point increments in the Quick Sepsis Related Organ Failure Assessment score for sepsis (aOR 2.25, 95% CI 1.50–3.47, p < 0.001), peptic ulcer disease (aOR 5.63, 95% CI 1.43–21.0, p = 0.01), and the receipt of immunosuppression prior to a blood culture draw (aOR 3.80, 95% CI 1.86–8.01, p < 0.001) were associated with an increased likelihood of speciating pathogenic Gram-positive bacilli from blood cultures such as Clostridium species and Listeria monocytogenes. Conclusion: Such predictors can help supplement a clinician’s assessment on determining when empirical therapy is indicated when faced with Gram-positive bacilli from blood cultures and may direct future stewardship interventions for responsible antimicrobial prescribing.
- Open Access
- 15 December 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e239
Implementing an antimicrobial stewardship medical student elective to impart good antibiotic prescribing habits early in medical training
Antibiotic prescribing behavior is a complex process influenced by socio-demographic, knowledge, attitudinal, patient, and system factors. 1 Formation of prescribing habits begins in medical school and is shaped through interactions with supervising physicians, patients, and the healthcare system. 2 These unique experiences contribute to variability in antibiotic prescribing observed across health systems. 3,
- 15 December 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e239
Open AccessImplementing an antimicrobial stewardship medical student elective to impart good antibiotic prescribing habits early in medical training
Antibiotic prescribing behavior is a complex process influenced by socio-demographic, knowledge, attitudinal, patient, and system factors. 1 Formation of prescribing habits begins in medical school and is shaped through interactions with supervising physicians, patients, and the healthcare system. 2 These unique experiences contribute to variability in antibiotic prescribing observed across health systems. 3,